Aims-To measure insulin-like growth factor-I (IGF-I) concentrations in the presence and absence of Helicobacter pylori infection and in response to eradication of the organism. Methods-An enzyme linked immunosorbent assay was used to measure gastric and fasting serum concentrations of IGF-I in 17 patients with and 11 without Hpylori infection. Repeat assessments were performed in the infected patients six weeks after they received a two week course of bismuth chelate, metronidazole, and amoxycillin. Results-IGF-I was detected at very low concentrations in gastric juice and in mucosal incubates. The median serum IGF-I concentration was 88 igIl in the patients infected with H pylori compared with 90 tgIl in the non-infected controls; IGF-I concentrations dropped to 77 tgIl following eradication therapy (p = 0.014). Conclusion-The similarity in baseline IGF-I concentrations in the presence and absence of H pylori suggests that their subsequent drop after treatment is more likely to be due to the treatment. (7 Clin Pathol 1996;49:676-678) Gastritis was classified according to the Sydney system and its activity graded on a scale from 0 to 3 as follows: 0 = normal; 1 = mild; 2 = moderate; and 3 = severe, depending on the intensity of neutrophilic infiltration. In patients infected with H pylori all assessments were repeated six weeks after completion of a two week eradication regimen, comprising metronidazole (400 mg three times daily), amoxycillin (500 mg three times daily) and bismuth chelate (De-Nol; 120 mg four times daily). IGF-I concentrations were measured using an enzyme linked immunosorbent assay, with a sensitivity of 10 ,tg/l, and using an antibody that does not cross-react with insulin,
The biochemical basis of the increased gastric mucosal cell proliferation observed in Helicobacter pylori gastritis' remains poorly understood. The action of Hpylori on the expression of insulin-like growth factor-I (IGF-I), an anabolic and mitogenic protein which has a key role in growth and development, is a possible cause of this increase in proliferation. Gastritis was classified according to the Sydney system and its activity graded on a scale from 0 to 3 as follows: 0 = normal; 1 = mild; 2 = moderate; and 3 = severe, depending on the intensity of neutrophilic infiltration. In patients infected with H pylori all assessments were repeated six weeks after completion of a two week eradication regimen, comprising metronidazole (400 mg three times daily), amoxycillin (500 mg three times daily) and bismuth chelate (De-Nol; 120 mg four times daily). IGF-I concentrations were measured using an enzyme linked immunosorbent assay, with a sensitivity of 10 ,tg/l, and using an antibody that does not cross-react with insulin, pro-insulin, or IGF-II.
Statistical analyses included the MannWhitney U test and the Wilcoxon's test for unpaired and paired data, respectively. Informed consent was obtained from all patients and all specimens were coded prior to analysis. The study was approved by the local Ethics Committee.
Results
Twenty nine patients were studied, 18 of whom were positive and 11 negative for H pylori infection. In the infected group the triple therapy regimen failed to eradicate H pylori in five patients. The baseline serum sample of one H pylori positive patient was lost during processing, and another patient refused triple therapy altogether. This left 28 patients (17 positive and 11 negative for H pylorn) with baseline specimens and 11 patients with specimens taken both before and after eradication therapy. 
IGF-I and H pylori gastritis

Discussion
This study shows that fasting serum IGF-I concentrations are not influenced by the presence of Hpylori gastritis, although they did fall significantly in response to a two week course of bismuth based triple therapy. With the increasing evidence linking Hpylori with gastric mucosal cell proliferation,' one could not exclude the possibility that IGF-I concentrations might be influenced by the presence of this organism. This was not confirmed by our study and suggests the involvement of other factors in Hpylori related mucosal cell proliferation.'
The similarity in IGF-I concentrations in patients with and without H pylori infection, with different grades of gastritis, suggests that it is unlikely that IGF-I is expressed in measurable amounts by the neutrophils in vivo, given the role of the neutrophils as an index of the activity of gastritis. This also explains the absence of high concentrations of IGF-I in gastric juice or tissue, as assessed in the present study.
There are two possible explanations for the drop in serum IGF-I concentrations following eradication of H pylori. The first relates to the normalisation of gastric histology. This, however, does not reconcile the differences in the activity of gastritis in patients with and without H pylori infection given the similarity in baseline IGF-I concentrations in these patients. The second, and probably the more likely explanation, is a direct inhibitory effect of bismuth based triple therapy on IGF-I production. This might explain another effect of triple therapy, thought to be independent of H pylori: it has been found that gastric mucosal cell proliferation decreased-that is, returned to normal four weeks after the intake of triple therapy, irrespective of the patient's H pylori status.' It will therefore be interesting, should ethical approval be forthcoming, to investigate the effect of triple therapy on Hpylori negative subjects when the consequences of eradication are studied.
The pathophysiological properties of IGF-I and the ability to produce it by recombinant DNA techniques have led to extensive testing of its "endocrine" activities. IGF-I stimulates glucose disposal in a manner similar to insulin and can increase insulin sensitivity,' raising the possibility of an application in insulin resistant syndromes.4 In catabolic subjects, intravenous IGF-I reverses nitrogen loss,5 whereas recovery from both ischaemic renal necrosis6 and dermal wounding7 can be accelerated by subcutaneous or local administration. However, IGF-I has also been linked to the development of a variety of neoplastic diseases including those of the breast, stomach, liver, and colon.8 9 To date, no agent has been shown to suppress IGF-I production, and this highlights the therapeutic potential of our findings.
In conclusion, H pylori infection does not seem to alter IGF-I concentrations despite the differences in the activity of gastritis in patients with and without H pylori infection. Fasting serum IGF-I concentrations are, however, sup- 
